Aptose Biosciences Inc. (APTO) Price Target Cut to $12.00 by Analysts at Royal Bank Of Canada
Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) had its price objective cut by Royal Bank Of Canada from $18.00 to $12.00 in a report published on Wednesday. They currently have an outperform rating on the stock.
Other analysts have also issued research reports about the company. Roth Capital reiterated a buy rating and set a $8.00 price objective on shares of Aptose Biosciences in a report on Friday, October 14th. Canaccord Genuity reiterated a buy rating and set a $7.00 price objective on shares of Aptose Biosciences in a report on Saturday, October 15th. Zacks Investment Research upgraded Aptose Biosciences from a sell rating to a hold rating in a report on Tuesday, October 11th. Finally, RBC Capital Markets reiterated an outperform rating on shares of Aptose Biosciences in a report on Tuesday, September 13th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Aptose Biosciences has an average rating of Buy and a consensus price target of $11.20.
Aptose Biosciences (NASDAQ:APTO) traded up 0.410% during mid-day trading on Wednesday, reaching $0.954. The company’s stock had a trading volume of 94,930 shares. The company’s market capitalization is $12.44 billion. Aptose Biosciences has a one year low of $0.83 and a one year high of $5.48. The stock has a 50-day moving average price of $1.71 and a 200-day moving average price of $2.26.
A hedge fund recently bought a new stake in Aptose Biosciences stock. Baker BROS. Advisors LP acquired a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 404,211 shares of the company’s stock, valued at approximately $909,000. Baker BROS. Advisors LP owned approximately 3.14% of Aptose Biosciences at the end of the most recent quarter. Institutional investors and hedge funds own 19.19% of the company’s stock.
About Aptose Biosciences
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Stock Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related stocks with our FREE daily email newsletter.